You are here: Industry Insights > writer

News List

Becoming a Pharma Product Writer for PharmaSources.com to Reach the Right Audience PharmaSources.com
October 22, 2020
Join us to be the best product writer who could provide real help with your readers in a post-pandemic era!
Novavax gets EC marketing authorization for Covid-19 vaccine By PBR Staff Writer Pharmaceutical-Business-Review
December 22, 2021
Developed using Novavax’ recombinant nanoparticle technology, the vaccine also known as NVX-CoV2373 is a protein-based Covid-19 vaccine candidate which is engineered from the genetic sequence of the initial SARS-CoV-2 virus strain.
Pfizer, BioNTech to supply Covid-19 vaccine paediatric doses to US By PBR Staff Writer Pharmaceutical-Business-Review
November 03, 2021
Pfizer and its partner BioNTech have announced that the US government has purchased additional paediatric doses of their Covid-19 vaccine, as it prepares for paediatric vaccinations.
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares firstwordpharma
August 17, 2021
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced closing of its previously announced underwritten public offering of 7,590,000 shares of its common stock at a public offering price of $19.00 per share
Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 04, 2021
Tenaya announced today the closing of its underwritten, upsized initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 1,800,000 additional shares of its common stock
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 04, 2021
Immuneering today announced the closing of its upsized initial public offering of 8,625,000 shares of Class A common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,125,000 shares of Class A common stock
Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 03, 2021
Rallybio Corporation today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common stock.
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 03, 2021
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares firstwordpharma
July 28, 2021
AzurRx BioPharma, Inc. announced today the closing of its previously announced underwritten public offering of 10,454,546 shares of common stock of the Company.
Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
July 21, 2021
Erasca, Inc. (Nasdaq: ERAS) today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 2,812,500 additional shares.